As such, clinical implementation of therapeutic agents targeting ErbB2, including trastuzumab and lapatinib, has achieved remarkable benefits in patients with ErbB2-overexpressing breast cancer; however, the development of resistance to these novel agents is emerging as a significant clinical challenge. Here, ERBB2 is linked to breast cancer.